Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes

Cancer Letters

Volumn 182, Issue 2, 2002, Pages 147-154

  Qiu, Zhao Hua ^a   Wu, Chu Tse ^a   Lao, Miao Fen ^a   Pan, Lu Zhe ^a   Li, Yuan Min ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Adenoviral vector; B7 1 costimulatory molecule; Combination gene therapy; Granulocyte macrophage colony stimulating factor; p53 tumor suppressor gene

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE THERAPY; HEP 2 CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; LARYNX CARCINOMA; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; WILD TYPE;

ADENOVIRIDAE; ANTIGENS, CD80; APOPTOSIS; CELL DIVISION; CELL LINE; CELL SURVIVAL; GENES, P53; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GREEN FLUORESCENT PROTEINS; HUMANS; KIDNEY; LARYNGEAL NEOPLASMS; LUMINESCENT PROTEINS; PROMOTER REGIONS (GENETICS); RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 0037190129     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00089-7     Document Type: Article

References (22)

1. Gene therapy for cancer: What have we done and where are we going?
2. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer
3. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus
4. The expression of multi-genes via a recombinant adenovirus and their effects of inducing apoptosis on lung cancer cells
5. Co-transfer of human wild-type p53 and granulocyte-macrophage colony-stimulating factor genes via recombinant adenovirus induces apoptosis and enhances immunogenicity in laryngeal cancer cells
6. Construction of recombinant adenovirus co-expressing human wild-type p53, GM-CSF and B7-1 genes
7. Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival
8. Parental gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
9. Molecular staging of head and neck squamous carcinoma
10. Gene-modified tumor cells as a cellular vaccine
11. Cancer vaccines
12. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic hu-PBL-SCID/Beige mouse-human glioblastoma multiforme model
13. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent specific and long-lasting antitumor immunity
14. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor
15. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells
16. Immunotherapy: Antigen, receptors and costimulation
17. B7-mediated costimulation and the immune response
18. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
19. Adenovirus as a system for delivering and expressing tumor suppressor genes in tumor cells
20. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulated CD8+ cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system
21. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro
22. B7-1 amplifies the response to interleukin-2 secreting tumor vaccines in vivo, but fails to induce a response to naÏve cells in vitro